30 September 2026
: Case report
[In Press] Fluorouracil-Associated Coronary Vasospasm and Reversible Cardiomyopathy Mimicking ST-Elevation Myocardial Infarction During a First Cycle of FOLFOX: A Case Report
Unusual clinical course, Adverse events of drug therapy
Ramez AlyacoubDOI: 10.12659/AJCR.954889
Am J Case Rep In Press; DOI: 10.12659/AJCR.954889
Available online: 2026-09-30, In Press, Corrected Proof
Publication in the "In-Press" formula aims at speeding up the public availability of the pending manuscript while waiting for the final publication. The assigned DOI number is active and citable. The availability of the article in the Medline, PubMed and PMC databases as well as Web of Science will be obtained after the final publication according to the journal schedule
Abstract
BACKGROUND
5-Fluorouracil (5-FU) is a mainstay chemotherapeutic agent for gastrointestinal malignancies but carries a recognized risk of cardiotoxicity, most often manifesting as coronary vasospasm that can mimic acute myocardial infarction. This report describes the case of a 50-year-old woman with ST-elevation myocardial infarction (STEMI) due to coronary artery vasospasm during continuous infusion of 5-FU as part of the first round of FOLinic acid (leucovorin), Fluorouracil (5-FU), and OXaliplatin (FOLFOX) chemotherapy for colorectal carcinoma.
CASE REPORT
A 50-year-old woman with colorectal carcinoma receiving her first cycle of FOLFOX developed severe chest pain during a continuous infusion of 5-FU. Initial emergency department evaluation was reportedly unremarkable, and she was discharged after symptomatic improvement with ketorolac. She returned emergently with recurrent crushing chest pain; a repeat electrocardiogram showed hyperacute T waves and ST-segment elevation, prompting ST-elevation myocardial infarction activation and transfer for emergent catheterization. Coronary angiography revealed no obstructive coronary artery disease. Echocardiography demonstrated a severely reduced left ventricular ejection fraction (LVEF) of 30% to 35% with apical akinesis, consistent with 5-FU-induced cardiomyopathy. 5-FU was permanently discontinued, and the patient was treated with vasodilator therapy, with complete resolution of symptoms and normalization of ventricular function on follow-up echocardiography.
CONCLUSIONS
5-FU can precipitate life-threatening coronary vasospasm and a fully reversible cardiomyopathy even during a first chemotherapy cycle, in the absence of obstructive coronary artery disease. Early recognition, prompt drug interruption, and a multidisciplinary cardio-oncology approach, including an individualized decision between permanent discontinuation and carefully supervised rechallenge, are essential to guide safe oncologic decision-making.
Keywords: Case Reports; Coronary Vasospasm; Fluorouracil; Colorectal Neoplasms; Cardiomyopathies
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.953338
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.954163
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.954178
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.954110
Most Viewed Current Articles
07 Dec 2021 : Case report
26,657,823
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347
06 Dec 2021 : Case report
179,911
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
21 Jun 2024 : Case report
123,656
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
08 May 2026 : Case report
93,398
DOI :10.12659/AJCR.952158
Am J Case Rep 2026; 27:e952158






